Plaque Rupture and Thrombosis
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent.
So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI.
READ THE VIEWPOINT HERE.
Stay updated with Hemostasis Today.
-
Nov 3, 2026, 01:51Cesar de Almeida Neto: Highlighting The Final Day of Hemo 2026
-
Nov 3, 2026, 01:34Jae Hyun Byun: Beyond Stenosis Understanding Carotid Plaque Instability
-
Nov 3, 2026, 01:20Smriti Yadav: A New Milestone in Transfusion Medicine
-
Nov 3, 2026, 00:55Dušan Ušjak: A Month of Research and Scientific Collaboration
-
Nov 3, 2026, 00:27Grace Gorecki: Early IVIG Accelerates Platelet Recovery in HIT
-
Nov 2, 2026, 22:15Micheline Mambue: A Case of Early Stent Thrombosis Successfully Managed With Repeat Angioplasty
-
Nov 2, 2026, 22:12Annie Bauzon: How the Body Produces Millions of Blood Cells Every Day
-
Nov 2, 2026, 22:11Anna Supernat: Does Leukocyte-Associated RNA Retention Affect Platelet-Based Cancer Classification?
-
Nov 2, 2026, 22:07Aabha Divya: Late Biatrial Thrombosis 31 Years After Heart Transplantation